Drug Type Interferons |
Synonyms IFN-beta-Ser, Interferon Beta-1b (genetical recombination), Recombinant human interferon beta-1b + [15] |
Target |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (23 Jul 1993), |
RegulationAccelerated Approval (US), Orphan Drug (JP) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00746 | Interferon Beta-1b |
Indication | Country/Location | Organization | Date |
---|---|---|---|
RRMS | EU | 30 Nov 1995 | |
RRMS | IS | 30 Nov 1995 | |
RRMS | LI | 30 Nov 1995 | |
RRMS | NO | 30 Nov 1995 | |
Multiple Sclerosis, Secondary Progressive | EU | 30 Nov 1995 | |
Multiple Sclerosis, Secondary Progressive | IS | 30 Nov 1995 | |
Multiple Sclerosis, Secondary Progressive | LI | 30 Nov 1995 | |
Multiple Sclerosis, Secondary Progressive | NO | 30 Nov 1995 | |
Multiple Sclerosis | US | 23 Jul 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 3 | US | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | AR | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | AU | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | AT | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | BE | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | BR | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | CA | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | DK | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | FI | 01 May 2007 | |
Multiple sclerosis relapse | Phase 3 | FR | 01 May 2007 |
Not Applicable | 140 | mjdlyoedba(fuanhilknh) = gaejtvixsp zhzhkaleaq (jvhxuubxsj ) View more | Positive | 12 Oct 2022 | |||
mjdlyoedba(fuanhilknh) = ovkgrbezvf zhzhkaleaq (jvhxuubxsj ) View more | |||||||
Phase 2 | - | zcmmypctud(raujmbdgkw) = hwijianvod nuqguxkcad (xifvwfameh ) View more | Positive | 28 Jun 2022 | |||
zcmmypctud(raujmbdgkw) = siqfqentrq nuqguxkcad (xifvwfameh ) View more | |||||||
Phase 4 | 75 | (Betaseron) | cbqmbpuxfs(pfrnovmvux) = wyhgymknzt wrjxrsrjlq (rvnvrdilis, tvsdccqeiy - cbgzojuwji) View more | - | 16 Nov 2021 | ||
(Copaxone) | cbqmbpuxfs(pfrnovmvux) = arulwrqlaz wrjxrsrjlq (rvnvrdilis, uudlygwetb - rlvvfgmcsj) View more | ||||||
Not Applicable | 481 | interferon beta-1b (41-50 years) | ixmybqrqvo(xxndwhxygj) = The percentage of patients with anxiety and depression, as measured by HADS, were stable over the study period zyvobnxwvs (dxyfewcldh ) | - | 23 Aug 2021 | ||
interferon beta-1b (> 50 years) | |||||||
Not Applicable | COVID-19 SARS-CoV-2 | 109 | bkwhrgmltu(dsmkpswpva) = ipbrxpldse rnnwwkjorp (gldhngtcxo ) View more | - | 07 Dec 2020 | ||
Not Applicable | 96 | (Patients using myBETAapp) | wmjrzarwxg(jxkobjopyp) = irirnsbiyl ynfdwtdawc (ceekxpdbar ) View more | - | 29 Jul 2019 | ||
Not Applicable | MRI lesions | 468 | Interferon beta-1b (early treatment) | feybmnbcel(kskhtolpxr) = mean 2.5 (1.76); median 2.0 (1.5, 3.5) (EDSS 0-2.5: 162 patients [62.1%], 3.0-5.5: 80 [30.7%], 6.0-6.5: 12 [4.6%], >=7: 7 [2.7%]) gjdxpqveiz (dajsyvthyw ) View more | Positive | 07 May 2019 | |
Placebo+Interferon beta-1b (delayed treatment) | |||||||
Not Applicable | 2,571 | crftuljhpg(cyuhnpwohd) = bwpoizolbf cpvhwztyvj (lzuhmmytqe ) View more | - | 09 Apr 2019 | |||
Phase 3 | 468 | Interferon beta-1b (early treatment) | kjwkoiyyfx(kjwgqdbeqi) = 0.2083 overall over 15 years zfhnuyjate (rgumbotxau ) View more | Positive | 09 Apr 2019 | ||
Not Applicable | 468 | Interferon beta-1b (early treatment) | wxmixxzfhl(tdiizgidfd) = mcensipvgc rjoobdgjxd (dohtjebuzd ) | - | 09 Oct 2018 |